Skip to content
Screener

Tandem Diabetes Care TNDM Operating Income

Operating Income at other companies

Insulet logo
InsuletPODD
$129.7M+7.1%
Medtronic logo
MedtronicMDT
$1.87B+30.4%
Beta Bionics logo
Beta BionicsBBNX
-$25.58M-28.7%
Embecta Corp. logo
Embecta Corp.EMBC
$48.7M-48.2%
AdaptHealth logo
AdaptHealthAHCO
$5.49M-76.3%
Mannkind logo
MannkindMNKD
-$350K-107%

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.29B+34.3%
Enterprise value$1.96B+46.2%
P/S1.2×+0.3×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Acquired in-process research and development expenses———75,217
Litigation and settlement expense—19,951—19,951
Total operating expenses158,572177,665312,794416,950
Operating loss(13,792)(51,810)(31,226)(172,688)
Other income (expense), net:
Interest income and other income, net1,225(632)4,8513,561
Interest expense(2,450)(1,905)(4,654)(3,767)
Loss from equity method investment(5,641)(3,375)(9,506)(6,917)

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's operating income?
Tandem Diabetes Care (TNDM) reported operating income of -$13.79M in Q2 2026.
How has Tandem Diabetes Care's operating income changed year-over-year?
Tandem Diabetes Care's operating income increased by 73.4% year-over-year, from -$51.81M to -$13.79M.
What is the long-term trend for Tandem Diabetes Care's operating income?
Over 4 years (2021 to 2025), Tandem Diabetes Care's operating income has grown at a 69.6% compound annual growth rate (CAGR), from $22.65M to -$187.26M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Tandem Diabetes Care's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude